Abstract recently submitted in anticipation of initial data analysis ahead of ESCCompany expects to report topline LEVEL results in AugustCHAPEL ...

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value ...

The ACGME has opened its Call for Sessions and will soon open the Call for Abstracts for the 2027 Annual Educational ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This page provides answers to the most commonly asked questions regarding abstract submission, confidentiality, and presentation policies. Questions are listed together at the top of the page for ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American ...

CHICAGO, May 26, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been ...

New preclinical data on MS 001 in combination with semaglutide selected for ADA Late Breaking Poster Session and ePoster Theater RIEHEN, BASEL, SWITZERLAND, April 28 ...

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines ...

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in ...

Abstract #9500: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study Intismeran autogene is ...